Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
In this study, researchers analyzed data from more than 450,000 adults with type 2 diabetes who started either a GLP-1 drug or a dipeptidyl peptidase-4 inhibitor (known as DPP-4 inhibitor)
The FDA has approved these medications for chronic weight management in adults with obesity (body mass index 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access
10Oral GLP-1 pill vs injection: which approach suits which research question
US$ 28.07
US$ 29.38
US$ 27.08
US$ 25.20
US$ 21.56
US$ 28.53
